|
|
 |
|
Viewing report
|
|
|
|
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
Decision Resources, Inc., July 2009, Pages: 43
Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention are the holy grails of autoimmune and inflammatory disease drug development. However, basic science and redundant biological pathways are holding back this therapy area. In this report, we investigate the autoimmune and inflammatory disease industry. We analyze 200 deals in this therapy area for 2007, 2008, and the first five months of 2009. We assess what types of deals companies are executing and what business strategies they are deploying for future success. We discuss recent industry-shaping events, industry drivers, and barriers that are holding back this therapy area.
Questions Answered in This Report
Analyzing deals opens up a window to a company’s business strategies.
- What do the 200 deals related to autoimmune and inflammatory diseases that took place in 2007, 2008, and the first five months of 2009 indicate about the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma?
- What technologies are hot?
- What new targets were licensed or optioned?
Three mega-mergers were announced in early 2009.
- What impact will these deals have on this therapy area?
- Why did Pfizer CEO Jeffrey Kindler think that Wyeth was the right answer for Pfizer?
- What trouble might Merck & Co. have with the Schering-Plough acquisition?
- What might prevent Roche from achieving its goals in its acquisition of Genentech?
The number of generics and branded generics is rising in some segments of this therapy area.
- Which diseases are seeing an increase in these types of agents and why?
- What do GlaxoSmithKline’s recent deals with Aspen Pharmacare and Dr Reddy’s Laboratories indicate about this company’s current strategies?
Understanding biological pathways and discovering biomarkers is key to future success in the autoimmune and inflammatory disease markets.
- What are the hurdles in this arena?
- What recent deals took place relating to pharmacogenomics?
- What gene discoveries may help in at least one disease area?
Companies have a continued passion for biologics.
- What are the recent deals in this area?
- What are the 16 licensed MAbs?
- The 11 recombinant proteins?
- The 8 peptides?
Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates.
- What are the top five most licensed technologies in our study period?
- What 37 nonbiologics product deals took place?
- What were the 16 new targets?
Scope
Therapy area: Diseases; market size, top 25 companies by worldwide sales, major brands.
200 deals: Total deal volume; biobucks; 20 largest deals; Big Biotech, Mid-Size Pharma and Big Pharma deals; most active disease areas; most active companies; top five deals by technology, outlicensing, divesting, new targets, biological pathways; nucleic acid therapeutics; budesonide deals; reformulations; inhaler issues; combination products.
Business strategies: Inlicensing, outlicensing, divesting low priority R&D programs, targeted acquisitions, benefits of a portfolio of modest products, milestone-driven dealmaking, shared development risk, emerging markets, generics markets, branded generics, life-cycle management, optimizing the commercialization of off-patent drugs, a passion for biologics, drug recycling and reformulations, fixed-dose combinations.
Industry-shaping events: Big Pharma consolidation, market entry, safety issues, change of ownership issues, reverse mergers, tumor necrosis factor-alpha (TNF-a) blockers, biotech’s financial crisis.
Industry outlook: Ten therapy area drivers; factors holding back this therapy area; annual growth rates for specific disease areas; three events that will invigorate the therapy area; two key harbingers of trouble to come.
Customers who bought this item also bought
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
Strategic Overview of the Autoimmune Biologics Market
Dealmaking and Industry Outlook in Niche Metabolic Diseases
Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition
Targeted Cancer Therapies: Novel Targets, Technologies, and Dealmaking
Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech 2nd Edition
|
|
|
|
